Fexofenadine inhibits the growth of B16 melanoma tumors that are resistant to anti-PD-1 monotherapy to the same extent as anti-PD-1 and anti-CTLA-4 combination therapy, further demonstrating a critical role for histamine signaling in tumor progression [71,191]. Here, PDCD1 is linked to neoplasm.